Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.39 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13790216 | 0.88 | CCR5 (0.38) | CCR5XPO1CA1CA4CA14 | |
| SCHEMBL11939968 | 0.78 | TUBB4A (0.37) | MEN1KMT2ATUBB4ATUBBTUBA3C | |
| SCHEMBL10097806 | 0.74 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL10114797 | 0.71 | PDCD4 (0.38) | XPO1CA1CA4CA14CA3 | |
| SCHEMBL12202938 | 0.70 | MEN1 (0.38) | CCR5CA1CA4CA14CA3 | |
| SCHEMBL15946714 | 0.70 | MEN1 (0.38) | CCR5CA1CA4CA14CA3 | |
| SCHEMBL14274136 | 0.65 | PDCD4 (0.38) | CCR5XPO1CA1CA4CA14 | |
| SCHEMBL17345370 | 0.64 | PDCD4 (0.43) | CCR5XPO1CA1CA4CA14 | |
| SCHEMBL17345371 | 0.64 | PDCD4 (0.36) | CCR5CA1CA4CA14CA3 | |
| SCHEMBL8885618 | 0.63 | PDCD4 (0.36) | CCR5CA1CA4CA14CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | MARTIN LOPEZ MA JESUS (ES) | 2012-07-26 | — | — | US | disclosed |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | MARTIN LOPEZ MA JESUS (ES) | 2012-07-26 | — | — | US | disclosed |
| EP-2032551-B9 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2012-02-29 | — | — | EP | disclosed |
| EP-2404912-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404913-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2032551-B1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2011-08-31 | — | — | EP | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | CCR5 3902/4885XPO1 2035/4885CA1 299/4885 |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | CCR5 3902/4885XPO1 2035/4885CA1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.